EHA 2019 | Impact of conditioning intensity of allo-SCT for AML with molecular residual disease

Christopher Hourigan

Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses his group’s work on the impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia (AML) with genomic evidence of residual disease. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter